200 mg/m2 melphalan as initial therapy in multiple myeloma:: A key to rapid achievement of complete remission.

被引：0
|
作者：
Powles, R
Sirohi, B
Singhal, S
Goyal, S
Treleaven, J
Lloyd, C
Kulkarni, S
Mehta, J
机构：
[1] Royal Marsden Hosp, Surrey, England
[2] Northwestern Univ, Sch Med, Chicago, IL USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5374
引用
收藏
页码：397B / 397B
页数：1
相关论文
共 50 条
  • [21] Prospective, randomized comparison between double mransplantation (T) with melphalan (200 mg/m2) and triple T with intermediate dose melphalan (100 mg/m2) in patients with multiple myeloma (an interim analysis).
    Ludwig, Heinz
    Linkesch, Werner
    Kasparu, Hedwig
    Krieger, Otto
    Spicka, Ivan
    Gastl, Gunther
    Greil, Richard
    Drach, Johannes
    Thaler, Josef
    Kuhn, Ingrid
    Zojer, Niklas
    Hinke, Axel
    BLOOD, 2006, 108 (11) : 878A - 879A
  • [22] Melphalan 140mg/m2 demonstrates identical clinical outcomes to melphalan 200mg/m2 amongst patients undergoing autologous transplant for multiple myeloma: a multicentre UK study
    Sangha, J.
    Cook, G.
    Rampotas, A.
    Ward, J.
    Cavenagh, J.
    Cook, M.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S72 - S73
  • [23] A prospective, randomized, phase III study of melphalan 200 mg/m2 (Mel200) versus melphalan 100 mg/m2 (Mel100) in newly diagnosed myeloma patients
    Palumbo, Antonio
    Bringhen, Sara
    Petrucci, Maria Teresa
    Falcone, Antonietta
    Liberati, Anna Marina
    Lauta, Vito Michele
    Grasso, Mariella
    Montanaro, Marco
    Pisani, Francesco
    Caravita, Tommaso
    Cangialosi, Clotilde
    Pregno, Patrizia
    Nozza, Andrea
    Calabrese, Elisabetta
    Gay, Francesca
    Cavallo, Federica
    Omede, Paola
    Musto, Pellegrino
    Foa, Robin
    Boccadoro, Mario
    BLOOD, 2007, 110 (11) : 223A - 223A
  • [24] Melphalan 200 mg/m2 (MEL200) versus melphalan 100 mg/m2 (MEL100) in newly diagnosed myeloma patients:: A prospective, randomized phase III study
    Bringhen, S.
    Petrucci, M. T.
    Falcone, A.
    Liberati, A. M.
    Omede, P.
    Pregno, F.
    Nozza, A.
    Palmas, A.
    Capaldi, A.
    Callea, V
    De Stefano, V
    Annino, L.
    Siniscalchi, A.
    Avonto, I
    Cavallo, F.
    Musto, P.
    Foa, R.
    Boccadoro, M.
    Palumbo, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 2 - 2
  • [25] MELPHALAN 200 MG/M2 (MEL200) VERSUS MELPHALAN 100 MG/M2 (MEL100) IN NEWLY DIAGNOSED MYELOMA PATIENTS: A PROSPECTIVE, RANDOMIZED PHASE III STUDY
    Boccadoro, M.
    Bringhen, S.
    Petrucci, M. T.
    Falcone, A.
    Liberati, A. M.
    Morandi, S.
    Gabbas, A.
    Capaldi, A.
    Callea, V.
    De Stefano, V.
    Bongarzoni, V.
    Rizzo, M.
    Calabrese, E.
    Cavallo, F.
    Gay, F.
    Omede, P.
    Musto, P.
    Foa, R.
    Palumbo, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 364 - 364
  • [26] Randomized Comparison of Melphalan 200 Mg/m2 v. 280 Mg/m2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
    Bensinger, William I.
    Becker, Pamela S.
    Gooley, Ted A.
    Chauncey, Thomas
    Maloney, David G.
    Vescio, Robert
    Gopal, Ajay K.
    Green, Damian J.
    Press, Oliver W.
    Lill, Michael
    Holmberg, Leona
    Ifthikharuddin, Jainulabdeen J.
    Phillips, Gordon L., II
    BLOOD, 2012, 120 (21)
  • [27] Evaluation of different intermediate melphalan doses (80 mg/m2 vs 100 mg/m2 vs 120 mg/m2) in multiple myeloma patients.
    Palumbo, A
    Triolo, S
    Argentino, C
    Bringhen, S
    Dominietto, A
    Giaccone, L
    Rus, C
    Omedè, P
    Pileri, A
    Boccadoro, M
    BLOOD, 1999, 94 (10) : 578A - 578A
  • [28] A prospective, randomized, phase III study of melphalan 200 mg/m2 (MEL200) versus melphalan 100 mg/m2 (MEL100) in newly diagnosed myeloma patients.
    Palumbo, Antonio
    Bringhen, Sara
    Petrucci, Maria Teresa
    Falcone, Antonietta
    Liberati, Anna Marina
    Grasso, Mariella
    Pisani, Francesco
    Caravita, Tommaso
    Pregno, Patrizia
    Nozza, Andrea
    Omede, Paola
    Falco, Patrizia
    Musto, Pellegrino
    Foa, Robin
    Boccadoro, Mario
    BLOOD, 2006, 108 (11) : 21A - 21A
  • [29] Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation
    R L Comenzo
    H Hassoun
    T Kewalramani
    V Klimek
    M Dhodapkar
    L Reich
    J Teruya-Feldstein
    M Fleisher
    D Filippa
    S D Nimer
    Leukemia, 2006, 20 : 345 - 349
  • [30] Survival outcomes following autologous stem cell transplant with melphalan 140mg/m2 versus 200mg/m2 preparative regimens in patients with multiple myeloma
    Sharma, Nidhi
    Benson, Evan
    Zhao, Qiuhong
    Nunnelee, Jordan
    Cottini, Francesca
    Elder, Patrick
    Rosko, Ashley
    Bumma, Naresh
    Khan, Abdullah
    Umyarova, Elvira
    Devarakonda, Srinivas
    Efebera, Yvonne A. A.
    Benson, Don M. M.
    LEUKEMIA & LYMPHOMA, 2023, 64 (07) : 1315 - 1321
12345